PT-141: Complete Research Guide

PT-141, known by its pharmaceutical name bremelanotide and marketed as Vyleesi®, holds a unique position among the peptides discussed on this site: it is one of the few that has achieved full regulatory approval as a prescription medication. Approved by the FDA in 2019 and subsequently by Health Canada, bremelanotide is the first and only on-demand treatment for acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women.

The compound was developed from Melanotan II after researchers observed significant pro-sexual effects during clinical trials for the tanning peptide. Palatin Technologies, the pharmaceutical company that developed bremelanotide, isolated the sexual function activity by creating a compound that primarily activates MC3R and MC4R melanocortin receptors in the central nervous system, with reduced activity at MC1R (the pigmentation receptor).

PT-141 represents a fundamentally different approach to treating sexual dysfunction compared to drugs like sildenafil (Viagra). While sildenafil works by increasing blood flow through PDE5 inhibition — a purely peripheral, vascular mechanism — PT-141 works centrally in the brain, modulating the neural pathways involved in sexual desire and arousal. This makes it the first centrally-acting drug approved specifically for sexual desire.

Bremelanotide (PT-141) is a synthetic cyclic heptapeptide with the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It is structurally very similar to Melanotan II — the primary difference is the C-terminal modification. While MT-II has an amidated C-terminus (-NH₂), PT-141 has a free carboxyl group (-OH). This seemingly minor structural change significantly alters the compound's receptor selectivity and pharmacological profile.

PT-141 has a molecular weight of approximately 1,025 Da and acts as a non-selective agonist at melanocortin receptors, with its primary therapeutic effects mediated through MC3R and MC4R activation. Its affinity for MC1R is lower than MT-II, which means PT-141 produces minimal pigmentation effects at therapeutic doses.

As the approved pharmaceutical product Vyleesi®, bremelanotide is formulated as a 1.75 mg subcutaneous injection in a single-use autoinjector. It is designed for on-demand use — administered at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than 8 doses per month.

The pharmacokinetics of bremelanotide show peak plasma concentration at approximately 1 hour after subcutaneous injection, with an elimination half-life of approximately 2.7 hours. The relatively short duration of action is suitable for its on-demand dosing regimen.

PT-141 works through a centrally-acting mechanism that is fundamentally different from other sexual dysfunction treatments.

Melanocortin Receptor Activation in the Brain: PT-141 crosses the blood-brain barrier and binds to MC3R and MC4R receptors in the hypothalamus and other brain regions involved in sexual response. These melanocortin receptors are part of the neural circuitry that regulates sexual desire, arousal, and motivation.

Downstream Neurotransmitter Modulation: Activation of MC4R triggers downstream signalling cascades that modulate the release of several neurotransmitters and neuropeptides involved in sexual behaviour: • Oxytocin release from the paraventricular nucleus of the hypothalamus • Dopamine modulation in reward and motivation pathways • Effects on serotonergic and noradrenergic systems

Central vs. Peripheral Mechanism: Unlike PDE5 inhibitors (sildenafil, tadalafil), which work purely on peripheral blood flow by preventing the breakdown of cGMP in smooth muscle tissue, PT-141 acts at the level of desire and arousal in the brain. This means it addresses the motivational and emotional components of sexual response, not just the mechanical/vascular aspects.

Gender-Neutral Pathway: The melanocortin system involved in sexual response appears to be similar in both men and women. Clinical trials demonstrated pro-sexual effects in both sexes, though the approved indication is currently limited to premenopausal women with HSDD. Research in men with erectile dysfunction has shown positive results, particularly in subjects who did not respond to sildenafil.

PT-141/bremelanotide has been studied in several clinical contexts, with its approved indication being the most extensively researched.

• Hypoactive Sexual Desire Disorder (HSDD) in Women: The RECONNECT Phase 3 clinical trials demonstrated that bremelanotide significantly increased sexual desire and reduced distress related to low sexual desire in premenopausal women with HSDD. Over 24 weeks, treated women showed clinically meaningful improvements on the Female Sexual Function Index (FSFI) desire domain and the Female Sexual Distress Scale (FSDS-R).

• Erectile Dysfunction in Men: Phase 2 clinical trials showed that PT-141 produced erections in men with erectile dysfunction, including subjects who were non-responsive to sildenafil. An intranasal formulation was initially developed for this application but was discontinued due to concerns about blood pressure effects. Current research interest continues with subcutaneous formulations.

• Female Sexual Arousal Disorder: Beyond desire, PT-141 has shown effects on genital arousal in women, as measured by vaginal photoplethysmography in clinical studies, suggesting its effects span both desire and physical arousal components.

• Haemorrhagic Shock: Interestingly, early preclinical research explored melanocortin agonists, including PT-141, for their potential to improve outcomes in haemorrhagic shock through their effects on cardiovascular function and inflammation.

• Melanocortin System Research: PT-141 serves as an important research tool for understanding the role of the melanocortin system in human sexual behaviour, appetite, and energy homeostasis.

Unlike most peptides on this site, PT-141 has well-defined, regulatory-approved dosing guidelines.

Approved Dosage (Vyleesi®): • 1.75 mg subcutaneous injection, self-administered in the abdomen or thigh • On-demand use: at least 45 minutes before anticipated sexual activity • Maximum: one dose per 24 hours • Maximum: 8 doses per month • Administered via a single-use, prefilled autoinjector

Research Dosages (Historical Clinical Trials): • Subcutaneous: doses ranged from 0.75 mg to 2.0 mg in clinical trials • Intranasal: 10–20 mg was used in earlier Phase 2 studies in men (this formulation was discontinued) • The 1.75 mg subcutaneous dose was selected for commercialisation based on the optimal balance of efficacy and tolerability

Important Considerations: • PT-141 should not be used in patients with uncontrolled hypertension or cardiovascular disease • Blood pressure monitoring is recommended before each dose • The drug may cause temporary increases in blood pressure • Alcohol should be avoided around dosing time as it may increase the risk of adverse effects • There is no continuous daily dosing regimen — Vyleesi is strictly on-demand

As an approved medication, PT-141/bremelanotide has a well-characterised safety profile from clinical trials.

Common Side Effects (>5% of patients): • Nausea (approximately 40% in clinical trials — the most frequently reported side effect) • Flushing (approximately 20%) • Injection site reactions (approximately 13%) • Headache (approximately 11%) • Temporary skin hyperpigmentation, particularly in areas with higher melanocyte density (face, gums, breasts)

Blood Pressure Effects: • Transient increases in systolic and diastolic blood pressure (typically 2–3 mmHg) and decreases in heart rate have been observed • These effects are generally mild and resolve within 12 hours • Contraindicated in patients with uncontrolled hypertension or cardiovascular disease

Hyperpigmentation: • Darkening of the skin, particularly on the face, gums, and breasts, can occur with repeated use • This is generally mild and may be reversible upon discontinuation but may not fully resolve in all patients

Drug Interactions: • Bremelanotide may slow gastric emptying. Oral medications that require rapid absorption should be taken at least 1 hour before or 2 hours after PT-141 administration • Caution is advised with naltrexone, as melanocortin effects may be reduced

Contraindications: • Uncontrolled hypertension or cardiovascular disease • Pregnancy (not indicated for postmenopausal women; Category X in pregnancy)

PT-141 (bremelanotide) as Vyleesi® has been approved by Health Canada for the treatment of acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women. This makes it one of the few peptides discussed on this site with full Canadian regulatory approval.

As a prescription medication, Vyleesi® can only be obtained through a licensed healthcare provider and dispensed by a pharmacy. It is available as a single-use, prefilled autoinjector containing 1.75 mg of bremelanotide.

The availability and cost coverage of Vyleesi® in Canada may vary by province. It is not universally listed on provincial drug formularies, meaning many patients may need to pay out-of-pocket or rely on private insurance coverage.

Important distinctions for Canadians: • The approved pharmaceutical product (Vyleesi®) is the only legally sanctioned form of PT-141 for human use in Canada • Research-grade PT-141 obtained from peptide suppliers is not equivalent to the pharmaceutical product and does not have the same quality assurances • Self-administration of research-grade PT-141 falls outside regulated medical practice • Healthcare providers can prescribe Vyleesi® off-label for indications beyond HSDD, though this is at the clinician's discretion and responsibility

Patients interested in PT-141 should consult a healthcare provider to discuss whether Vyleesi® is appropriate for their situation, rather than seeking unregulated research-grade alternatives.